What Is Brepocitinib, and How Does It Work?

Brepocitinib is a prescription medication belonging to a class of drugs known as Janus kinase (JAK) inhibitors—more specifically, it targets TYK2 (tyrosine kinase 2) and JAK1 enzymes. Developed to treat a range of immune-mediated conditions, brepocitinib offers a new way to interrupt the inflammatory signals that drive diseases such as plaque psoriasis and alopecia areata.

Key Points
• Brepocitinib is an oral, small-molecule inhibitor of TYK2 and JAK1.
• It’s FDA-approved for moderate to severe plaque psoriasis and alopecia areata.
• By blocking cytokine signaling, it helps reduce inflammation and abnormal immune responses.
• Common side effects may include upper respiratory infections, headache and lab changes.
• Patients need regular monitoring, including blood tests, to track safety and effectiveness.

What Is Brepocitinib?

• Classification: A selective, dual TYK2/JAK1 inhibitor taken by mouth once daily.
• Approvals:
– June 2023, FDA approval for moderate to severe plaque psoriasis in adults.
– September 2023, FDA approval for adults and adolescents (12 years and older) with alopecia areata.
• Formulations: Supplied as 30 mg tablets; dosing varies by condition and patient factors.

Why Brepocitinib Matters

• Traditional treatments for psoriasis and alopecia areata include topical creams, phototherapy and injectable biologics.
• Brepocitinib offers an oral option with a targeted mechanism—patients may prefer a pill over injections or infusions.
• Dual TYK2/JAK1 inhibition may deliver broad control of multiple inflammatory pathways.

How Brepocitinib Works

Our immune system relies on signaling proteins—called cytokines—to coordinate responses to infection or injury. In autoimmune conditions, certain cytokine signals run amok, triggering inflammation and tissue damage. Brepocitinib disrupts this process by:

1. Blocking TYK2 and JAK1 Enzymes
   • TYK2 and JAK1 are intracellular enzymes that relay cytokine signals from cell surface receptors to the nucleus.
   • Key cytokines affected include interleukins (IL-12, IL-23) and interferons (IFN-α, IFN-γ).
   • By inhibiting these enzymes, brepocitinib dampens multiple pro-inflammatory pathways at once.

2. Reducing Immune Cell Activation
   • With cytokine signaling interrupted, immune cells such as T cells and dendritic cells are less likely to trigger skin inflammation (in psoriasis) or attack hair follicles (in alopecia areata).
   • This leads to improvements in skin clearing and hair regrowth over time.

3. Providing Oral Convenience
   • Unlike biologics that require injections or infusions, brepocitinib comes as a daily pill—no needles, no clinic visits for administration.

Conditions Treated

Plaque Psoriasis
• A chronic autoimmune skin disease marked by red, scaly patches.
• Brepocitinib studies demonstrated significant skin clearance (measured by PASI scores) compared to placebo and some existing therapies.

Alopecia Areata
• An autoimmune form of hair loss; patients experience patchy or total loss of scalp and body hair.
• Clinical trials showed brepocitinib promotes hair regrowth in many patients, with results appearing as early as 12–24 weeks.

Potential Future Uses (Under Investigation)
• Atopic dermatitis (eczema)
• Inflammatory bowel disease
• Systemic lupus erythematosus
• Other autoimmune conditions

Efficacy: What the Trials Show

• Plaque Psoriasis
– Up to 75% of patients achieved PASI 75 (75% reduction in disease severity) at week 16.
– Significant proportions reached PASI 90 or better by week 24.
• Alopecia Areata
– Nearly half of treated patients saw 50% or more scalp hair regrowth by week 24.
– A subset achieved nearly complete regrowth (SALT score improvements ≥ 90%).

Safety and Side Effects

Most patients tolerate brepocitinib well, but as with any immune-modulating drug, side effects and lab abnormalities can occur. Commonly reported issues include:
• Upper respiratory tract infections (nasopharyngitis, sinusitis)
• Headache
• Nausea
• Elevated liver enzymes or lipid levels on blood tests
• Changes in blood counts (neutropenia, anemia)

Less common but more serious risks:
• Serious infections (e.g., tuberculosis, opportunistic infections)
• Blood clots (venous thromboembolism)
• Major adverse cardiovascular events (MACE)
• Malignancies (lymphoma, skin cancers)

Risk Mitigation Strategies
• Screen for latent infections (tuberculosis, hepatitis) before starting.
• Regular lab monitoring: complete blood count, liver function tests, lipids.
• Assess for risk factors such as smoking, obesity, diabetes or prior clotting events.
• Vaccinations: update before treatment, avoid live vaccines during therapy.

Who Should Consider Brepocitinib?

Ideal candidates are adults (and in alopecia areata, adolescents 12 years and up) who:
• Have moderate to severe plaque psoriasis not adequately controlled by topical therapies, phototherapy or other systemic drugs.
• Experience significant hair loss from alopecia areata affecting quality of life.
• Prefer an oral medication over injectable biologics.
• Are willing to undergo periodic lab tests and clinical follow-up.

Who Should Avoid It

• People with active serious infections.
• Those with a history of recurrent or opportunistic infections.
• Patients with known hypersensitivity to brepocitinib or its ingredients.
• Pregnant or breastfeeding individuals—safety hasn’t been established.
• Patients with a high risk of blood clots, serious heart disease or certain cancers.

Starting and Stopping Brepocitinib

• Dosing, on average, is 30 mg once daily for psoriasis; alopecia areata regimens may vary.
• If you miss a dose, take it as soon as you remember—do not double up.
• Do not stop abruptly without discussing with your healthcare provider; flare-ups can occur.

Monitoring Your Treatment

• Initial evaluation: complete medical history, infection screening, baseline labs.
• Follow-up visits: every 3 months (or as recommended) to check symptoms and labs.
• Adjustments: based on side effects, lab changes or response to therapy.

Questions to Ask Your Doctor

• Is brepocitinib right for my condition and health history?
• What laboratory tests will I need, and how often?
• How long before I can expect to see improvement?
• What should I watch for in terms of side effects?
• Can brepocitinib be combined safely with my other medications?

Next Steps

If you’re experiencing symptoms of psoriasis or alopecia areata and wondering if brepocitinib might help, you can start by doing a free, online symptom check, using the doctor approved Ubie Symptom Checker. From there, schedule an appointment with a dermatologist or your primary care provider to discuss:
• Your medical history and current symptoms
• Potential benefits and risks of brepocitinib
• Whether this treatment fits into your overall care plan

Always speak to a doctor about anything that could be life threatening or serious. Regular communication with your healthcare team ensures the safest, most effective use of brepocitinib—or any new therapy.